Introduction
DNA repair processes represent potential new targets for combating cellular resistance to certain anticancer drugs (1) . Repair of DNA damage proceeds through different pathways i.e. reversion, excision, or tolerance (2) which depend on various parameters in which the chemistry of DNA modification plays a central role. Most DNA damage is repaired by nucleotide excision repair which recognizes DNA adducts induced by numerous chemical treatments (3) . This mechanism consists of two distinct major steps: (i) the incision reaction involving damage recognition and excision of the damaged oligonucleotide and (ii) repair synthesis of new DNA using the complementary strand as a template and its subsequent ligation to restore strand continuity (2) . Until recently, procedures used to quantitate DNA repair activity were technically too cumbersome and time consuming to be used for evaluating numerous compounds as potential DNA repair inhibitors (1, 4, 5) . The methodology used here is based on the in vitro excision repair assay initially developed by Wood et al. (6) adapted into a solid-phase assay and named the 3D (Damaged DNA Detection) assay (7) . This 3D assay takes advantage of damaged plasmid DNA adsorption in sensitized plastic microwells (8) and has been used to detect DNA damage induced by genotoxic agents (7) . With this 3D assay, we have characterized the inhibitory activity of a panel of 18 known anticancer drugs and four additional antibiotics. We have demonstrated that this assay permits a rapid and simple assessment of DNA repair inhibition by confirming certain results obtained with other methodologies (9) (10) (11) (12) and have shown that actinomycin D, distamycin A, doxorubicin and mithramycin A are very potent in vitro inhibitors of DNA repair.
Results and discussion
Bleomycin was purchased from Roger Bellon, camptothecin from Cipla, methotrexate from Fluka, mitoxantrone from Lederle, and vindesine from Lilly. Etoposide, etopofos and vinorelbine were provided by Pierre Fabre Médicament. All others compounds tested were purchased from Sigma. Vindesine, vinorelbine, 5-fluoracil (5-FU*), mitomycin C, bleomycin, doxorubicin, mitoxantrone, and mithramycin A were solubilized in water. Melphalan and chlorambucil were solubilized in a buffered ethanolic solution, as described by Hill et al. (13) , while 5% DMSO was used as solvent for all other compounds. HeLa cells were obtained from Computer Cell Culture Center. Damaged and undamaged pBS plasmids were prepared and irradiated with UVC-light as described earlier (6) .
This 3D assay used takes advantage of plasmid DNA adsorption onto polylysine-coated microplates and luminometric detection which provide an easier and more sensitive methodology for quantification of DNA repair. The 3D assay kit (S. F. R. I., Berganton, France) contains all the constituents, except the test compounds. The assay protocol is summarized in Figure 1 . Plasmid DNA adsorption Fifty microlitres of 1 µg/ml of UVC-damaged (A) or undamaged (B) pBS plasmids were distributed in each sensitized well (8) and incubated for 30 min at 30°C in a microplate incubator (IEMS, Labsystems) to permit adsorption. Any nonadsorbed DNA was then eliminated by three washes with a washing buffer containing PBS and 0.1% Tween 20.
DNA repair reaction
Test compounds were co-incubated for 3 h at 30°C with a reaction mixture containing: 120 µg of a whole-cell extract of HeLa cells, 70 mM KCl, 0.4 µM each of dGTP, dCTP, dATP, and digoxygenylated-dUTP in reaction buffer containing 40 mM Hepes-KOH (pH 7.6), 5 mM MgCl 2 , 0.5 mM dithiotreitol, 2 mM EGTA, 10 mM phosphocreatine, 50 µg/ml creatine phosphate, and 360 µg/ml of bovine serum albumin. During this reaction, DNA damage was recognized and the excised patches were replaced by neosynthesized DNA fragments. Throughout this DNA synthesis, digoxygenylated-dUMPs were incorporated. The DNA repair reaction was stopped by three washes. Quantitation of DNA repair activity An anti-digoxygenin antibody conjugated with alkaline phosphatase (diluted 1/10 000 in PBS plus 0.025% acetylated bovine serum albumin and 0.1% Nonidet P40) was distributed in each well so that during a 30 min incubation at 30°C the digoxygenylated-dUMP incorporated could be recognized. After five washes, a solution of 'Lumi-Phos 530' (Lumigen), a substrate for alkaline phosphatase, was added for 15 min at 30°C. Light emitted by the dephosphorylated 'Lumi-Phos 530' was measured using a luminometer (Luminoskan, Labsystems) and expressed in relative luminometric units (RLUs). Under these experimental conditions, the luminometric signal was proportional to the digoxygenylated-dUMP incorporated, and thus, to the DNA repair activity. Control experiments with undamaged pBS plasmids provided the background signal, which were subtracted systematically from the corresponding values obtained using UVC-damaged plasmids. Resulting data were defined as the in vitro DNA repair activity.
The 3D assay used for detecting DNA damaging agents was performed essentially as described previously (7), except that after the plasmid DNA adsorption step, the test compound was pre-incubated with undamaged plasmids for 3 h at 30°C. Test compounds were then eliminated by five washes before allowing the DNA repair reaction to occur, as described above. DNA-damaging activity was expressed as a ratio of the DNA repair activity measured with solvent only and was derived from three experiments carried out with triplicates.
Results of evaluating 22 compounds for their DNA repair inhibitory and DNA damaging activities using these 3D assays are summarized in Tables I and II . The largest grouping, detailed in Table I did not damage DNA, with E max values ranging from 1.1 to 1.4 at a concentration of 100 µM. In terms of DNA repair inhibition, six compounds showed definite activity, with IC 50 values ranging from 0.42 to 18 µM, whilst the other 12 were judged inactive (IC 50 Ͼ100 µM). Taking as examples, actinomycin D, an inhibitor of DNA transcription and replication, as a compound which inhibited DNA repair and taxol, an alkaloid stabilising microtubules, as one which did not, the detailed results obtained are shown in Figure 2 . For taxol, inactivity was characterized by the lack of variation of DNA repair activity, even at the highest concentration tested (100 µM) ( Fig. 2A) . To determine the concentration of test compounds, such as actinomycin D, that inhibit DNA repair by 50% (IC 5 -value), two to five experiments, using intermediate concentrations, were performed. These results were translated into percentage values of those obtained with solvent only and were defined as the in vitro repair activity (Fig. 2B ). Figure 2B clearly shows a concentration-dependent decrease of DNA repair activity resulting from the inhibitory effect of increasing concentrations of actinomycin D, with an IC 50 -value of 0.42 µM (Table I ). This was considered as representative of potent in vitro inhibitory activity, certainly relative to aphidicolin, a polymerase inhibitor currently used as a reference inhibitor of DNA synthesis, with an IC 50 of 0.81 µM. Amongst the series of 18 non-DNA-damaging anticancer or antibiotic drugs studied, only certain DNA-interacting agents tested were found clearly to inhibit DNA repair at micromolar concentrations or lower (Table I) : namely, actinomycin D, doxorubicin, distamycin A, mithramycin A. Results with doxorubicin and distamycin A confirm those presented by Popanda and Thielmann using another technique (10), whereas these appear to be the first published results concerning this activity of actinomycin D and mithramycin A, which were the stronger inhibitors, with IC 50 values of 0.42 and 0.44 µM, respectively (Table I) , stronger even than aphidicolin. Doxorubicin and mithramycin A were less effective, with similar IC 50 -values of 2.4 µM. These inhibitory activities might stem, nonexclusively, from (i) interaction with protein(s) of the cell-free extract, (ii) interaction with DNA, (iii) an interference with the recognition of damage and/or its excision, (iv) an inhibition of DNA polymerases involved in the repair synthesis.
Most of the other compounds tested with the 3D assay were not found to inhibit DNA repair (Table I ). This was not unexpected for the tubulin-interacting drugs (e.g. taxol, vinorelbine, and vindesine) since they have never been described as inhibitors of any process of DNA metabolism. Similar inactivity was expected and found with compounds known to require bioactivation (e.g. mitomycin C, Ara-C and 5-FU) (14, 15) , and for those which only influence DNA repair activity indirectly via nucleotide metabolism (e.g. methotrexate) (16) . Interestingly, compounds tested which stabilize cleavable complexes with topoisomerase I or II (e.g. camptothecin, etoposide and etopofos) were also shown not to inhibit DNA repair (Table I ). The influence of topoisomerase II activity on DNA repair processes remains controversial (17, 18) . Our results are in agreement with those obtained using different in vitro methodologies (9) (10) (11) (12) .
Using the 3D assay following the protocol described by Salles et al. (7), we observed concentration-dependent alterations in DNA repair activity with undamaged plasmid in the presence of four compounds: bleomycin, chlorambucil, melphalan, and mitoxantrone indicating the presence of induced DNA damage (Table II) . Representative data for bleomycin and melphalan are shown in Figure 3A . The E max values of 15.2 and 17.3, showed that chlorambucil and melphalan, respectively covalently bound to DNA, have been clearly recognized by DNA repair processes, whilst the recognition of damage due to bleomycin and mitoxantrone, with E max values of 7.6 and 3.0 respectively, was clearly lower (Table II) . Such damage was probably associated with the oxidizing activity of these former compounds (19, 20) , known to be dependent on the presence in the medium of cationic or enzymatic catalysts.
In terms of DNA repair activity, as shown in Figure 3B , bleomycin and melphalan, respectively provided examples of compounds judged to be either inhibitory or non-inhibitory of DNA repair. In the presence of melphalan, RLUs increased in a concentration-dependent manner and to the same extent with damaged or undamaged plasmids (Fig. 3B) . Thus, the difference between RLUs obtained with damaged and undamaged plasmids was essentially constant for all concentrations of melphalan tested. This result suggests that there was no variation of DNA repair activity and that the increase of luminometric signal was due to the recognition of melphalandamaged DNA by the DNA repair proteins. In the presence of bleomycin, the luminometric signals also increased up to a concentration of 10 µM, suggesting that bleomycin stimulated DNA repair or that some DNA damage due to bleomycin were recognized. However, in this case, the difference between the RLUs obtained with damaged or undamaged plasmids decreased in a concentration-dependent manner, suggestive of inhibition of DNA repair. At concentrations up to 10 µM The DNA-damaging activity of bleomycin (m) or melphalan (d) was confirmed with an experiment using the 3D assay kit as described previously (7) . An example of a compound without any DNAdamaging activity, taxol (n), is also presented. The DNA-damaging activity is expressed at a ratio calculated, for each concentration tested, as follows: bleomycin, inhibition was so efficient that it induced a decline in the RLUs (Fig. 3B) , which could be explained mechanistically by interactions with DNA and/or protein, but could also be due to a high extent of DNA damage, especially DNA strand breaks. Results with mitoxantrone and chlorambucil essentially mirrored those obtained with bleomycin and melphalan, respectively, reflecting their positive and negative inhibitory effects on DNA repair (Table II) . The resultant IC 50 values derived from three experiments for mitoxantrone and bleomycin were 18 and 78 µM, respectively, indicating rela-2444 tively weak inhibition of DNA repair (Table II) . Thus, results obtained with the DNA-damaging agents were complex and should be considered more an estimation, rather than a definite quantitation of DNA repair inhibitory activity, because of the biphasic effects resulting from their apparent 'mixture' of DNA damaging activity and repair inhibition (Fig. 3) . Nevertheless, using this 3D assay procedure, it has been possible readily to distinguish between inhibitors of DNA repair, such as bleomycin and mitoxantrone, and non-inhibitors of DNA repair, such as chlorambucil and melphalan (Fig. 3B) .
Conclusions
In conclusion, this new chemiluminescent assay has permitted detection of the marked inhibitory activities of aphidicolin, distamycin A, doxorubicin, mitoxantrone and coumermycin A1 and the weak-or non-inhibitory activities of camptothecin, etoposide and amsacrine. Thereby, confirming results obtained with more complicated methods like the original in vitro repair replication assay or alkaline elution (10, 12) . We have also demonstrated that actinomycin D, distamycin A, mithramycin A, and doxorubicin are very potent inhibitors of in vitro DNA repair and their precise enzymatic targets are currently under investigation.
We propose that this assay may be useful in rationally selecting new compounds to combine with DNA-damaging agents, so as increase their cytotoxic potency as previously investigated with a combination of aphidicolin plus an alkylating agent (21) (22) (23) or with a combination of fludarabine triphosphate and cisplatin (24) . Another perspective might involve use of these DNA repair inhibitors as novel means of circumventing mechanisms of cellular resistance to anticancer drugs, associated with enhanced DNA repair activities.
